Carl Lokko Organon ( NYSE: OGN ) and partner Shanghai Henlius Biotech said that a phase 3 trial of their biosimilar to Roche's ( OTCQX:RHHBY ) Perjeta (pertuzumab) met its primary endpoint. That endpoint was the total pathological complete response (tpCR). Secondary endpoints still under evaluation include tpCR rate assessed by investigators; breast.
